肿瘤的过继性细胞免疫疗法  

Adoptive cellular immunotherapy for cancer

作　　者：尚艺曼[1] 王子兵[1] 马一杰[1] 张勇[1] 高全立[1] 

机构地区：[1]郑州大学附属肿瘤医院河南省肿瘤医院生物治疗科,450008

出　　处：《国际肿瘤学杂志》2013年第2期103-106,共4页Journal of International Oncology

摘　　要：肿瘤过继性细胞免疫治疗（ACI）是通过调动机体免疫功能以达到消除和控制肿瘤的目的，具有靶向疗效明显、不良反应轻微等优点。细胞因子诱导的杀伤细胞和肿瘤浸润淋巴细胞已广泛用于临床并取得初步疗效。随着特异性转基因T细胞的发展及临床应用，免疫治疗的疗效将进一步增加。目前，改善细胞培养方法、增强细胞本身功能以及联合其他治疗是进一步提高ACI疗效的关键。Adoptive cellular immunotherapy （ACI） achieves the elimination and control ol tumor by mobilizing the body＇s immune function. It also has targeted efficacy and mild untoward effects. Cytokineinduced killer cells and tumor-infiltrating lymphoeytes have been widely used in clinic and have obtained preliminary efficacy. With the development and clinical application of the specific gene transfer of T cell, it will further increase the efficacy of immunotherapy. At present, improving cell culture technology and cell function and using with other treatment are the key links to improve the efficacy of ACI.

关 键 词：肿瘤 免疫疗法 杀伤细胞 

分 类 号：R730.5[医药卫生—肿瘤]